M&A Deal Summary

Keensight Capital Acquires 3PBiovian

On February 1, 2024, private equity firm Keensight Capital acquired life science company 3PBiovian

Acquisition Highlights
  • This is Keensight Capital’s 9th transaction in the Life Science sector.
  • This is Keensight Capital’s 2nd transaction in Finland.

M&A Deal Summary
Date 2024-02-01
Target 3PBiovian
Sector Life Science
Buyer(s) Keensight Capital
Deal Type Buyout (LBO, MBO, MBI)

Target

3PBiovian

Turku, Finland
3PBIOVIAN is a globally operating Contract Development and Manufacturing Organization (CDMO), delivering end-to-end services for biotech and pharma companies. 3PBiovian's service offering includes microbial and mammalian protein expression platforms, viral vector production for adenoviruses and adenoassociated viruses, cell therapy, and plasmid DNA production. Additionally, 3PBiovian provide fill and finish services for recombinant proteins and viral vectors. 3PBiovian is based in Turku, Finland.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Keensight Capital

Investor Investor Investor Investor Investor

Category Private Equity Firm
Founded 2000
PE ASSETS 5.5B EUR
Size Mega
Type Sector Agnostic
DESCRIPTION

Keensight Capital is a private equity investment firm focused on majority and minority growth capital investments in Western European companies. Keensight makes equity investments in a number of situations including the provision of capital to finance growth, either organically or through acquisitions, or the buying out of existing shareholders. The Firm looks to invest €10 to €600 million and will consider business with up to €400 million in revenue. Keensight Capital was formed in 2000 and is based in Paris.

DEAL STATS #
Overall 48 of 50
Sector (Life Science) 9 of 9
Type (Buyout (LBO, MBO, MBI)) 16 of 18
Country (Finland) 2 of 2
Year (2024) 1 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2024-02-01 Biovian

Turku, Finland

Biovian is a one-stop-shop GMP (Good Manufacturing Practice) CDmO of biopharmaceuticals providing manufacturing and development services from early stage to finished product. Biovian’s broad service offering includes comprehensive analytical solutions to support drug substance and drug product development and release, as well as analytical and microbiological testing of investigational and commercial drug substances, drug products or medical devices. Biovian was founded in 2003 and is based in Turku, Finland.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2024-02-06 Plat4mation

Utrecht, Netherlands

Plat4mation is a global pure-play ServiceNow Elite partner. The Company helps ServiceNow customers across the entire value chain, offering a comprehensive suite of advisory, implementation, and managed services solutions. Plat4mation was founded in 2013 and is based in Utrecht, Netherlands.

Buy -
Mergr

Product

Company

Legal